Lye, L.-F.; Chou, R.-H.; Wu, T.-K.; Chuang, W.-L.; Tsai, S.C.-S.; Lin, H.-J.; Tsai, F.-J.; Chang, K.-H.
Administration of Bevacizumab and the Risk of Chronic Kidney Disease Development in Taiwan Residents: A Population-Based Retrospective Cohort Study. Int. J. Mol. Sci. 2024, 25, 340.
https://doi.org/10.3390/ijms25010340
AMA Style
Lye L-F, Chou R-H, Wu T-K, Chuang W-L, Tsai SC-S, Lin H-J, Tsai F-J, Chang K-H.
Administration of Bevacizumab and the Risk of Chronic Kidney Disease Development in Taiwan Residents: A Population-Based Retrospective Cohort Study. International Journal of Molecular Sciences. 2024; 25(1):340.
https://doi.org/10.3390/ijms25010340
Chicago/Turabian Style
Lye, Lon-Fye, Ruey-Hwang Chou, Tsai-Kun Wu, Wu-Lung Chuang, Stella Chin-Shaw Tsai, Heng-Jun Lin, Fuu-Jen Tsai, and Kuang-Hsi Chang.
2024. "Administration of Bevacizumab and the Risk of Chronic Kidney Disease Development in Taiwan Residents: A Population-Based Retrospective Cohort Study" International Journal of Molecular Sciences 25, no. 1: 340.
https://doi.org/10.3390/ijms25010340
APA Style
Lye, L.-F., Chou, R.-H., Wu, T.-K., Chuang, W.-L., Tsai, S. C.-S., Lin, H.-J., Tsai, F.-J., & Chang, K.-H.
(2024). Administration of Bevacizumab and the Risk of Chronic Kidney Disease Development in Taiwan Residents: A Population-Based Retrospective Cohort Study. International Journal of Molecular Sciences, 25(1), 340.
https://doi.org/10.3390/ijms25010340
